Wan Tai Biological: Nine-valent HPV vaccine approved for market launch

Wan Tai Biotechnology announced that its wholly-owned subsidiary, Xiamen Wan Tai Canghai Biotechnology Co., Ltd., has received approval for the marketing of a nine-valent human papillomavirus vaccine. The vaccine is suitable for females aged 9-45, with a two-dose regimen for ages 9-17 and a three-dose regimen for ages 18-45. Prior to this, there was only one nine-valent HPV vaccine on the market globally, Merck's Gardasil9. The approval of the marketing license for the nine-valent HPV vaccine will benefit the promotion and use of the company's HPV vaccine, enrich the company's product line, further enhance the company's core competitiveness, and lay a solid foundation for the company's continued stable development.